Skip to main content

Table 1 Clinical data, imaging abnormalities, and SSTR 2 expression

From: Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with 68Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy

Clinical data

Imaging abnormalities

SSTR 2

Pt no

Age/sex

Stage

Previous therapy

Gr

Dg

PFS (months)

OS (months)

Follow-up (months)

V T1-Gad (cm 3 )

DOTA

SUVmax

BP

C

H

L

1

49/F

Primary

 

III

A

  

29.4

0.57

TOC

0.79

−0.26

0

2

B

2

62/F

Primary

 

III

A

  

14.4

1.71

NOC

1.22b

NA

0

2

B

3

44/F

Primary

 

III

A

  

21.0

0

NOC

c

1

3

B

4

49/M

Primary

 

III

A

  

13.0

0

NOC

3

3

C

5

57/F

Primary

 

III

A

10.4

 

12.5

0.16

NOC

0.69

−0.47

0

0

6

18/M

Primary

 

III

A

10.9

 

11.8

0

NOC

0

3

B

7

49/F

Primary

 

III

A

  

10.7

0.81

NOC

0.69 d

NA

1

3

C

8

32/F

Primary

 

III

A

8.4

 

13.8

0

X

X

X

0

1

C

9

54/F

Primary

 

III

O

13.6

 

27.7

0.03

NOC

3

3

B

10

60/M

Primary

 

III

OA

  

21.6

0

NOC

3

3

B

11

71/M

Primary

 

IV

GBMO

0

1.2

 

1.91

NOC

3.07

1.41

0

3

M

12

37/M

Primary

 

IV

GBMO

  

21.0

4.32

NOC

0.99

−0.62

3

3

B

13

35/F

Primary

 

IV

GBM

0

13.7

 

1.27

TOC

0.65

0.39

0

1

C

14

63/F

Primary

 

IV

GBM

24.0

 

24.1

12.2

NOC

2.21

0.98

0

0

15

62/F

Primary

 

IV

GBM

0

7.3

 

11.5

NOC

3.01

1.26

0

0

16

67/F

Primary

 

IV

GBM

0

4.4

 

14.8

NOC

1.62

0.36

0

1

B

17

70/M

Primary

 

IV

GBM

0

1.0

 

21.5

NOC

2.85

1.80

0

3

M

18

76/F

Primary

 

IV

GS

0

0.9

 

34.7

NOC

3.73

1.75

0

3

M

19

28/M

Recurrent

S

III

A

81.2

 

106.1

0

NOC

1

3

B

20

51/M

Recurrent

S, RT

III

O

60.9

 

253.7

0

NOC

3

3

B

21

42/F

Recurrent

S, S, RT, S

III

OA

24.3

99.5

 

0

NOC

3

3

C

22

46/M

Recurrent

S, RT, C

III

OA

39.0

100.4

 

28.2

NOC

5.68

3.33

1

1

C

23

42/F

Recurrent

S, CRT

IV

GBM

24.0

37.1

 

0.04

TOC

0.46

−0.34

0

3

B

24

68/F

Recurrent

S, CRT

IV

GBM

23.1

26.3

 

27.9

NOC

2.40

1.57

0

0

25

64/F

Recurrent

S, CRT

IV

GBM

34.2

38.2

 

12.8

NOC

2.70

1.07

0

3

B

26

42/F

Recurrent

S, CRT

IV

GBM

5.5

13.6

 

28.0

NOC

2.44

2.28

0

3

B

27

61/F

Recurrent

S, RT

IV

sGBM

16.1

21.3

 

2.59

NOC

1.98

0.64

0

2

C

28

57/M

Recurrent

S, CRT

IV

GBM

11.0

27.5

 

3.03a

NOC

3.26

2.33

0

3

B

  1. Pt no, patient number; F, female; M, male; Gr, grade; Dg, diagnosis; A, astrocytoma; O, oligodendroglioma; OA, oligoastrocytoma; GBMO, glioblastoma with oligodendroglioma component; GBM, glioblastoma; sGBM, secondary GBM; GS, gliosarcoma; S, surgery; RT, radiotherapy; C, chemotherapy (temozolomide); CRT, chemoradiotherapy with adjuvant temozolomide; Dx, dexamethasone; TOC, 68Ga-DOTATOC; NOC, 68Ga-DOTANOC; −, no tracer uptake; X, no PET performed; NA, not applicable; C, intensity of most common staining (0 to 3); H, highest staining intensity (0 to 3); L, location of staining; C, cytoplasmic; M, membranous; B, both. aNo MRI (cardiac pacemaker), tumor volume defined from contrast-enhanced CT; bstatic PET 28 to 58 min post-injection (mild claustrophobia); cdynamic PET discontinued at 53 min post-injection (dyspnea); ddynamic PET discontinued at 36 min post-injection (numbness of the arm).